Core Viewpoint - The company, Valiant Bio-B (09887.HK), announced that five research abstracts have been selected for presentation at the 67th Annual Meeting of the American Society of Hematology (ASH), highlighting its innovative drug candidates LBL-034 and LBL-076 [1] Group 1: Research Highlights - The clinical study of LBL-034 has been chosen for the first oral presentation on the first day of the conference, showcasing the latest efficacy and safety data for patients with relapsed/refractory multiple myeloma [1] - Multiple research results have been accepted for the 67th ASH meeting, indicating strong recognition from the international academic community regarding the company's research and innovation capabilities [1] Group 2: Company Recognition - The company has consistently presented its innovative drug development results at international platforms such as ASH and the American Society of Clinical Oncology (ASCO) over the years [1]
维立志博-B(09887.HK)研究摘要入选第67届ASH年会展示